INT1578

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1975
Last Reported 2010
Negated 1
Speculated 1
Reported most in Abstract
Documents 52
Total Number 55
Disease Relevance 20.62
Pain Relevance 17.18

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (PRL) cytosol (PRL) extracellular region (PRL)
Anatomy Link Frequency
plasma 4
lactotrophs 4
anterior pituitary 4
liver 2
thyrotrophs 2
PRL (Homo sapiens)
Pain Link Frequency Relevance Heat
Dopamine 750 100.00 Very High Very High Very High
Morphine 59 100.00 Very High Very High Very High
narcan 58 99.98 Very High Very High Very High
opiate 67 99.92 Very High Very High Very High
agonist 325 99.86 Very High Very High Very High
antagonist 204 99.86 Very High Very High Very High
Endogenous opioid 31 99.72 Very High Very High Very High
dopamine receptor 127 99.70 Very High Very High Very High
Inflammation 22 99.34 Very High Very High Very High
Opioid 41 99.32 Very High Very High Very High
Disease Link Frequency Relevance Heat
Galactorrhea 1256 100.00 Very High Very High Very High
Endometriosis (extended) 15 100.00 Very High Very High Very High
Stress 55 99.68 Very High Very High Very High
Prolactinoma 124 99.60 Very High Very High Very High
Hepatotoxicity 9 99.44 Very High Very High Very High
INFLAMMATION 23 99.34 Very High Very High Very High
Systemic Lupus Erythematosus 105 98.92 Very High Very High Very High
Rheumatoid Arthritis 4 98.80 Very High Very High Very High
Pituitary Cancer 66 98.78 Very High Very High Very High
Sleep Disorders 28 98.76 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Higher doses of naloxone (30 mg) do not further inhibit the PRL secretion induced by fenfluramine.
Negative_regulation (inhibit) of Localization (secretion) of PRL associated with narcan
1) Confidence 0.59 Published 1985 Journal Clin. Endocrinol. (Oxf) Section Abstract Doc Link 3987071 Disease Relevance 0 Pain Relevance 0.72
Naloxone reduces the fenfluramine-induced prolactin release in man.
Negative_regulation (reduces) of Localization (release) of prolactin associated with narcan
2) Confidence 0.59 Published 1985 Journal Clin. Endocrinol. (Oxf) Section Title Doc Link 3987071 Disease Relevance 0 Pain Relevance 0.72
They observed that naloxone is not able to reduce either basal PRL secretion in menopausal women, or puerperal hyperprolactinemia, or PRL release induced by mechanical breast stimulation.
Negative_regulation (reduce) of Localization (release) of PRL associated with galactorrhea, endometriosis (extended) and narcan
3) Confidence 0.59 Published 1983 Journal Acta Eur. Fertil. Section Abstract Doc Link 6326452 Disease Relevance 0.38 Pain Relevance 0.51
They observed that naloxone is not able to reduce either basal PRL secretion in menopausal women, or puerperal hyperprolactinemia, or PRL release induced by mechanical breast stimulation.
Negative_regulation (reduce) of Localization (secretion) of PRL associated with galactorrhea, endometriosis (extended) and narcan
4) Confidence 0.59 Published 1983 Journal Acta Eur. Fertil. Section Abstract Doc Link 6326452 Disease Relevance 0.38 Pain Relevance 0.51
These data support the hypothesis that alpha-adrenergic receptors are involved in the inhibition of PRL secretion.
Negative_regulation (inhibition) of Localization (secretion) of PRL
5) Confidence 0.59 Published 1978 Journal Endocrinology Section Abstract Doc Link 217617 Disease Relevance 0 Pain Relevance 0.26
Effect of piperoxane on serum prolactin: possible role of epinephrine-mediated synapses in the inhibition of prolactin secretion.
Negative_regulation (inhibition) of Localization (secretion) of prolactin in synapses
6) Confidence 0.59 Published 1978 Journal Endocrinology Section Title Doc Link 217617 Disease Relevance 0 Pain Relevance 0.22
Methysergide decreases prolactin release after FK 33-824 [Tyr-D-Ala-Gly-MePhe-Met(o)-ol], a potent analogue of methionine enkephalin.
Negative_regulation (decreases) of Localization (release) of prolactin associated with enkephalin
7) Confidence 0.59 Published 1984 Journal Psychopharmacology (Berl.) Section Title Doc Link 6431476 Disease Relevance 0 Pain Relevance 0.23
This increase is possibly the result of a weak inhibition of prolactin secretion, due to down-regulation of beta-adrenergic receptors, and/or enhanced activity of prolactin stimulating serotoninergic receptors (Baumgartner et al 1988).
Negative_regulation (inhibition) of Localization (secretion) of prolactin
8) Confidence 0.59 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376090 Disease Relevance 0.14 Pain Relevance 0.16
The dopamine-mediated inhibition of prolactin secretion occurs through the binding of D2 receptors on the membrane of lactotroph cells and involves several signal transduction systems, resulting in inhibition of prolactin gene transcription, reduction of prolactin synthesis and release.
Negative_regulation (inhibition) of Localization (secretion) of prolactin in lactotroph associated with dopamine
9) Confidence 0.59 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376090 Disease Relevance 0 Pain Relevance 0.26
Cholinomimetic drugs with central effect, such as physostigmine, have been differently reported either to have no effect, to increase, or to inhibit prolactin release, though physostigmine may produce significant increases in plasma prolactin concentrations in humans after intravenous infusion.
Negative_regulation (inhibit) of Localization (release) of prolactin in plasma
10) Confidence 0.59 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376090 Disease Relevance 0.38 Pain Relevance 0.17
It was demonstrated that exposure to bright light for 2 h at night caused a decrease in prolactin secretion, which surpassed significantly the decline one would expect by sleep deprivation only (P less than 0.01).
Negative_regulation (decrease) of Localization (secretion) of prolactin associated with sleep disorders
11) Confidence 0.59 Published 1990 Journal J. Pineal Res. Section Abstract Doc Link 2352119 Disease Relevance 0.10 Pain Relevance 0
Since the prolactin levels in adult RA depend on the inflammatory activity, and the physiological prolactin secretion decreases in chronic stress (especially sleep disorders), these results are most likely to be explained as reactive non-specific mechanisms in the stress of the disease.
Negative_regulation (decreases) of Localization (secretion) of prolactin associated with stress, inflammation, rheumatoid arthritis, disease and sleep disorders
12) Confidence 0.58 Published 1996 Journal Baillieres Clin Rheumatol Section Abstract Doc Link 8911653 Disease Relevance 1.44 Pain Relevance 0.15
When cells were preincubated with bromocriptine [6.6 +/- 4.8 (SD) X 10(-11) M], EKC (10(-11) to 10(-9) M) antagonized, in a dose-dependent manner, the dopaminergic inhibition of PRL release.
Negative_regulation (inhibition) of Localization (release) of PRL
13) Confidence 0.58 Published 1985 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 2995431 Disease Relevance 0.33 Pain Relevance 1.03
Seeing that substituted benzamides affect prolactin secretion, the plasmatic levels of prolactin and dopamine, a known factor inhibiting prolactin release, were studied as well.
Negative_regulation (inhibiting) of Localization (release) of prolactin associated with dopamine
14) Confidence 0.58 Published 1981 Journal Pathol. Biol. Section Abstract Doc Link 6262702 Disease Relevance 0.34 Pain Relevance 0.47
Seeing that substituted benzamides affect prolactin secretion, the plasmatic levels of prolactin and dopamine, a known factor inhibiting prolactin release, were studied as well.
Negative_regulation (inhibiting) of Localization (release) of prolactin associated with dopamine
15) Confidence 0.58 Published 1981 Journal Sem Hop Section Abstract Doc Link 6269192 Disease Relevance 0.34 Pain Relevance 0.47
It is concluded that the dopamine modulation of electrical activity involving calcium current may be an early important step in the mechanism by which dopamine inhibits PRL release.
Negative_regulation (inhibits) of Localization (release) of PRL associated with dopamine
16) Confidence 0.58 Published 1985 Journal Endocrinology Section Abstract Doc Link 4029087 Disease Relevance 0.07 Pain Relevance 0.59
However, stimulators and inhibitors of PRL secretion such as TRH, bromocriptine or dopamine have no effect on dPRL release.
Negative_regulation (inhibitors) of Localization (secretion) of PRL associated with dopamine
17) Confidence 0.58 Published 1992 Journal Endocrinology Section Abstract Doc Link 1597150 Disease Relevance 0 Pain Relevance 0.11
It is a potent and very long-acting inhibitor of prolactin secretion.
Negative_regulation (inhibitor) of Localization (secretion) of prolactin
18) Confidence 0.58 Published 1995 Journal Drugs Section Abstract Doc Link 7729332 Disease Relevance 0.23 Pain Relevance 0.05
PRL secretion is inhibited by dopamine, and defects in DA metabolism have been described in patients with SLE.
Negative_regulation (inhibited) of Localization (secretion) of PRL associated with dopamine and systemic lupus erythematosus
19) Confidence 0.57 Published 2009 Journal Pediatr Rheumatol Online J Section Body Doc Link PMC2770548 Disease Relevance 1.42 Pain Relevance 0.40
In humans, mu- and kappa-opioid receptor agonists lower tuberoinfundibular dopamine, which tonically inhibits prolactin release.
Negative_regulation (inhibits) of Localization (release) of prolactin associated with dopamine, agonist and kappa opioid receptor
20) Confidence 0.57 Published 2005 Journal Neuropsychopharmacology Section Abstract Doc Link 15988468 Disease Relevance 0.07 Pain Relevance 0.43

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox